Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX

LPL Financial Holdings, Enphase Energy, United Therapeutics, ShockWave Medical and ChampionX are included in this Analyst Blog.

HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery

HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's healthcare facilities for undergoing surgeries.

Syneos Health (SYNH) to Enhance Clinical Trials With New Pact

Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

Investors are optimistic about IDEXX (IDXX) owing to strong international growth.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Nalak Das headshot

Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left

we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.

QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval

QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.

IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise

IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails

Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

Thermo Fisher (TMO) Expands Global Footprint With New Facility

Thermo Fisher's (TMO) new facility in China is a strategic addition to the company's global pharma services network.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.

After Plunging 10.9% in 4 Weeks, Here's Why the Trend Might Reverse for Shockwave Medical (SWAV)

Shockwave Medical (SWAV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AmerisourceBergen (ABC) to Repurchase Common Stock Worth $200M

AmerisourceBergen (ABC) announces a share repurchase worth $200 million in concurrence with the sale of its shares by one of its shareholders, Walgreens Boots Alliance, under Rule 144.

Boston Scientific's (BSX) New Buyout to Expand Global Presence

Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.

LabCorp (LH) Gains on Innovation Amid Currency Headwinds

LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.

Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access

Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.

Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.

LabCorp's (LH) New APH Lab to Expand Global Capabilities

LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.

Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome

Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles

Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.